BIOPHYTIS S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.85 EUR | 0.00% |
|
+1.19% | -58.33% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 3.64M 3.38M |
|---|---|---|---|---|---|
| Net income 2022 | -24M -22.29M | Net income 2023 | -17M -15.79M | EV / Sales 2022 | - |
| Net Debt 2022 | 3.53M 3.28M | Net Debt 2023 | 2.7M 2.51M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.33
x | P/E ratio 2023 |
-0.16
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 40.58% |
More Fundamentals
* Assessed data
Biophytis S.A. is a biotechnology company in the clinical stage specialized in the development of drug candidates to slow degenerative processes and improve functional capacity in patients with age-related diseases, including respiratory failure in patients suffering from COVID-19.
The company is located in Paris, France and Cambridge, Massachusetts.
Calendar
2024-10-28
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- ALBPS Stock
- ALBPS Stock
